SNB Portfolio Adjustments
Swiss National Bank Cuts Southern Company, Danaher, and CVS Health Stakes in Q4
Anonymous
Key Points
1
In Southern Company filings, Swiss National Bank said it cut its stake by selling 153,600 shares in the fourth quarter, bringing holdings to 3,014,500 shares; the article also notes hedge funds and other institutional investors own 64.10% of Southern’s stock.
2
For Danaher, the report highlights that investment research firms adjusted expectations alongside the ownership changes—Goldman Sachs cut its Danaher target price from $265.00 to $230.00 and kept a “buy” rating, while Evercore raised its target from $225.00 to $232.00 with an “outperform” rating.
3
The CVS executive-trading item included detailed figures: EVP Tilak Mandadi sold 69,551 shares at an average price of $89.58 for about $6,230,378.58, reducing his direct holding to 10,133 shares (an 87.28% decrease).
4
In CVS, Swiss National Bank’s stake size was also specified as roughly 0.27% of the company (about $275.828 million) as of its most recent SEC filing, with hedge funds and other institutional investors owning 80.66% of CVS stock.
The Swiss National Bank trimmed its stakes in four major U.S. companies during the fourth quarter of 2025, filing the changes with the SEC in February 2026. The cuts were nearly uniform — each position reduced by roughly 4.7% to 4.9% — consistent with the SNB's policy of routine index rebalancing rather than targeted stock picking, according to Reuters.
The largest holding by value remains Danaher at $404.3 million, followed by CVS Health at $275.8 million, Southern Company at $262.9 million, and Emerson Electric at $204.7 million. All four reductions reflect the SNB's passive, market-cap-weighted approach to its $173 billion U.S. equity portfolio.
SNB Sold 153,600 Southern Shares in One Quarter
The Swiss National Bank sold 153,600 shares of Southern Company in Q4 2025, bringing its total holding to 3,014,500 shares worth about $262.9 million, according to SEC filings. The SNB now owns a small slice of a company where hedge funds and other institutions control 64.10% of all shares.
The SNB does not pick stocks based on company fundamentals. Instead, it buys and sells to mirror global indices like the MSCI World. When a stock's weight shifts in the index, the SNB adjusts its position to stay "market-neutral," SNB Chairman Martin Schlegel explained in April 2026. "We weight companies according to their market capitalization to cover the market as broadly as possible," he said, adding that "our process is very robust," per Reuters.
Goldman Cuts Danaher Target as Analysts Split on Recovery
The SNB's Danaher stake fell 4.9% to 1,766,008 shares valued at $404.3 million. Analyst views on Danaher are divided. Goldman Sachs cut its price target from $265 to $230, citing a sluggish bioprocessing equipment market, while keeping a "buy" rating. Evercore took the opposite tone, raising its target from $225 to $232 with an "outperform" rating, per Investing.com.
CEO Rainer Blair has pointed to "improved momentum in Diagnostics and Life Sciences" as evidence of a steady turnaround, according to Reuters. Still, Goldman's analysts argue that pharmaceutical companies are lagging on capital spending, capping near-term upside even if the long-term story remains intact.
CVS Executive Sold 87% of His Stake for $6.2 Million
Alongside the SNB's 4.7% cut to 3,475,660 CVS Health shares worth $275.8 million, a senior CVS executive made a far more dramatic move. EVP Tilak Mandadi sold 69,551 shares on May 8, 2026 at an average price of $89.58 per share, collecting about $6,230,378, according to SEC Form 4 filings. That sale cut his direct holding from roughly 79,684 shares down to just 10,133 — an 87.28% reduction.
Market watchers are treating the sale with caution. While executive sales are often pre-planned, an 87% liquidation at a near-$90 price point is being described as a "positioning reset" by analysts at Stock Titan. Institutions still own 80.66% of CVS stock overall, providing a broad base of support beneath the share price.
Why a Swiss Central Bank Owns Billions in U.S. Utility Stocks
The SNB's U.S. equity holdings exist because of Swiss franc management, not investment ambition. The bank prints francs to buy foreign currencies and prevent the franc from rising too high. Those dollars are then invested in global stocks, making the SNB one of the world's largest passive equity holders, per SWI swissinfo.ch. By 2026, its U.S. equity book topped $173 billion.
Critics want the SNB to use that clout differently. Activist group Notre BNS argues the bank should push companies on climate policy rather than staying silent. The SNB rejects that framing. Under Swiss law, it excludes firms tied to severe environmental damage or human rights violations but otherwise acts as a non-voting shareholder, per Reuters.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
30
Articles
36
Reach
66
A
AnonymousAuthor
